Literature DB >> 15242423

Glucocorticoid regulation of the inflammatory response to injury.

M P Yeager1, P M Guyre, A U Munck.   

Abstract

During the first half of the 20th century, physiologists were interested in the adrenal glands primarily because adrenalectomized animals failed to survive even mild degrees of systemic stress. It eventually became clear that hormones secreted by the adrenal cortex were critical for survival and, in this context, adrenal cortical hormones were widely considered to support or stimulate important responses to stress or injury. With the purification and manufacture of adrenal cortical hormones in the 1930s and 1940s, clinicians suddenly discovered the potent anti-inflammatory actions of glucocorticoids (GCs). This dramatic, and unexpected, discovery has dominated clinical and laboratory research into GC actions throughout the second half of the 20th century. More recent research is again reporting GC-induced stimulatory effects on a variety of inflammatory response components. These effects are usually observed at low GC concentrations, close to concentrations that are observed in vivo during basal, unstimulated states. For example, GC-mediated stimulation has been reported for the hepatic acute-phase response, for cytokine secretion, expression of cytokine/chemokine receptors, and for the pro-inflammatory mediator, macrophage migration inhibition factor. It seems clear that the long-held clinical view that GCs act solely as anti-inflammatory agents needs to be re-assessed. Varying doses of GCs do not lead simply to varying degrees of inflammation suppression, but rather GCs can exert a full range of effects from permissive to stimulatory to suppressive.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15242423     DOI: 10.1111/j.1399-6576.2004.00434.x

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand        ISSN: 0001-5172            Impact factor:   2.105


  42 in total

1.  Hydrocortisone at stress-associated concentrations helps maintain human heart rate variability during subsequent endotoxin challenge.

Authors:  Athos J Rassias; Paul M Guyre; Mark P Yeager
Journal:  J Crit Care       Date:  2011-04-21       Impact factor: 3.425

Review 2.  Innate immune responses and chronic obstructive pulmonary disease: "Terminator" or "Terminator 2"?

Authors:  Robert P Schleimer
Journal:  Proc Am Thorac Soc       Date:  2005

3.  [Introduction to the topic: How much hydrocortisone does the patient really need? The (anti-)stress hormone in the perioperative phase].

Authors:  J Briegel
Journal:  Anaesthesist       Date:  2005-07       Impact factor: 1.041

Review 4.  An inflammatory review of glucocorticoid actions in the CNS.

Authors:  Shawn F Sorrells; Robert M Sapolsky
Journal:  Brain Behav Immun       Date:  2006-12-27       Impact factor: 7.217

Review 5.  Glucocorticosteroids in football: use and misuse.

Authors:  J Dvorak; N Feddermann; K Grimm
Journal:  Br J Sports Med       Date:  2006-07       Impact factor: 13.800

6.  Glucocorticoids exert opposing effects on macrophage function dependent on their concentration.

Authors:  Hee-Young Lim; Nora Müller; Marco J Herold; Jens van den Brandt; Holger M Reichardt
Journal:  Immunology       Date:  2007-04-23       Impact factor: 7.397

Review 7.  11beta-HSD1, inflammation, metabolic disease and age-related cognitive (dys)function.

Authors:  Karen E Chapman; Jonathan R Seckl
Journal:  Neurochem Res       Date:  2007-10-25       Impact factor: 3.996

8.  Cortisol exerts bi-phasic regulation of inflammation in humans.

Authors:  Mark P Yeager; Patricia A Pioli; Paul M Guyre
Journal:  Dose Response       Date:  2010-08-12       Impact factor: 2.658

Review 9.  Scientific and clinical challenges in sepsis.

Authors:  Luis Ulloa; Michael Brunner; Laura Ramos; Edwin A Deitch
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

Review 10.  Therapeutic manipulation of glucocorticoid metabolism in cardiovascular disease.

Authors:  Patrick W F Hadoke; Javaid Iqbal; Brian R Walker
Journal:  Br J Pharmacol       Date:  2009-02-23       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.